Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 8/20 | 0.74 |
| ▸ | TNF | P01375 | 5/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22272376 | 0.88 | PDE4D (0.57) | PDE4DTNF | |
| SCHEMBL24519364 | 0.84 | PDE4D (0.74) | PDE4DTNF | |
| SCHEMBL22264687 | 0.84 | PDE4D (0.73) | PDE4DTNF | |
| SCHEMBL29735388 | 0.84 | PDE4D (0.73) | PDE4DTNF | |
| SCHEMBL29735350 | 0.84 | PDE4D (0.73) | PDE4DTNF | |
| SCHEMBL22264617 | 0.84 | PDE4D (0.73) | PDE4DTNF | |
| SCHEMBL22264648 | 0.84 | PDE4D (0.73) | PDE4DTNF | |
| SCHEMBL20838993 | 0.77 | PDE4D (0.63) | PDE4DTNF | |
| SCHEMBL20838992 | 0.77 | PDE4D (0.63) | PDE4DTNF | |
| SCHEMBL20851945 | 0.74 | PDE4D (0.62) | PDE4DTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365204-B2 | Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | UNION therapeutics A/S (DK) | 2022-06-21 | — | — | US | disclosed |
| US-20200239493-A1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239493-A1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE7A, PDE12 | PDE4D 11/4885TNF 969/4885 |
| US-11365204-B2 | Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | PDE4A, PDE7A, PDE12 | PDE4D 11/4885TNF 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.